Sugi Predict

Sugi Predict / Compounds / SCHEMBL671759

SCHEMBL671759

SCHEMBL671759

COc1ccc2c(C=O)c[nH]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 1.00
▸ MAPT P10636 3/20 1.00
▸ KDM4E B2RXH2 2/20 1.00
▸ CYP1A2 P05177 1/20 0.77
▸ CYP2C19 P33261 1/20 0.77
▸ CYP2A6 P11509 2/20 0.58
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ APOBEC3A P31941 1/20 0.57
▸ APOBEC3G Q9HC16 1/20 0.57
▸ CDK4 P11802 1/20 0.54
▸ CCND1 P24385 1/20 0.54
▸ GAA P10253 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ GFER P55789 1/20 0.52
▸ IMPDH2 P12268 1/20 0.51
▸ PLG P00747 1/20 0.51
▸ PLAU P00749 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954469 1.00 ALDH1A1 (1.00) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL1093746 0.87 ALDH1A1 (1.00) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL13152910 0.83 MAPT (0.71) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL13548412 0.83 ALDH1A1 (0.70) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL29957546 0.83 ALDH1A1 (0.70) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL15323127 0.80 MAPT (0.64) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL29957922 0.80 ALDH1A1 (0.66) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL2539684 0.80 ALDH1A1 (0.66) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL11097545 0.80 ALDH1A1 (0.80) ALDH1A1MAPTKDM4ECYP1A2CYP2C19
SCHEMBL2537557 0.80 ALDH1A1 (0.66) ALDH1A1MAPTKDM4ECYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117886642-A Selenium-rich nutrient solution for tartary buckwheat production and application 成都大学 2024-04-16 — — CN claimed
US-12187736-B2 Selective estrogen receptor degraders and uses thereof INVENTISBIO LLC (US) 2025-01-07 — — US disclosed
US-12012411-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-18 — — US disclosed
CN-117886642-A Selenium-rich nutrient solution for tartary buckwheat production and application 成都大学 2024-04-16 — — CN disclosed
US-20240043442-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF INVENTISBIO LLC 2024-02-08 — — US disclosed
CN-110526854-B Alpha, beta-unsaturated ketone derivative, preparation method and application thereof as medicine 宁夏医科大学 2023-12-15 — — CN disclosed
CN-117209411-A Synthesis method of indolal and derivative thereof 苏州翔实医药发展有限公司 2023-12-12 — — CN disclosed
CN-109824664-B Antineoplastic indole alkaloid compounds and preparation method and application thereof 广州中医药大学(广州中医药研究院) 2022-06-07 — — CN disclosed
US-20220106321-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-04-07 — — US disclosed
US-11279704-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-03-22 — — US disclosed
WO-2004019943-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MEMORY PHARMACEUTICALS CORPORATION (US) 2004-03-11 — — WO disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO disclosed
EP-0915870-B1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION HOFFMANN LA ROCHE (CH) 2002-09-25 — — EP disclosed
EP-0680950-B1 PROPENONE DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 2001-05-23 — — EP disclosed
US-6228877-B1 ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS HOFFMANN-LA ROCHE INC. 2001-05-08 — — US disclosed
US-5952355-A 1-ETHER-SUBSTITUTED PHENYL-3-INDOL-3-YL-2-PROPEN-1-ONE DERIVATIVES; ANTITUMOR AND -CARCINOGENIC AGENTS; IMMUNOSUPPRESSANTS; AUTOIMMUNE DISEASES; SIDE EFFECT REDUCTION KYOWA HAKKO KOGYO CO., LTD. (JP) 1999-09-14 — — US disclosed
EP-0915870-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 1999-05-19 — — EP disclosed
WO-1998004551-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 1998-02-05 — — WO disclosed
EP-0680950-A1 PROPENONE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 1995-11-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187736-B2 Selective estrogen receptor degraders and uses thereof ESR1, ESRRA, ESR2 ALDH1A1 413/4885MAPT 4204/4885KDM4E 808/4885
US-11279704-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885MAPT 3097/4885KDM4E 1372/4885
US-20240043442-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF ESR1, ESRRA, ESR2 ALDH1A1 413/4885MAPT 4204/4885KDM4E 808/4885
US-20220106321-A1 VIRAL REPLICATION INHIBITORS EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885MAPT 3097/4885KDM4E 1372/4885
US-12012411-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 ALDH1A1 4277/4885MAPT 3097/4885KDM4E 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.